TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Bronstein, Gewirtz & Grossman Llc
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Skye Bioscience alleging false and misleading statements about the effectiveness and prospects of their drug nimacimab during the period of November 4, 2024 to October 3, 2025.

Insights
NVO   neutral

Presented a competing proposal but facing potential legal challenges from Pfizer and scrutiny from FTC


SKYE   negative

The lawsuit alleges the company made materially false statements about their drug's effectiveness, clinical prospects, and regulatory potential, suggesting significant misrepresentation of the company's actual status